Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.789832
Title: Aberrant TGFβ/BMP signalling in connective tissue disease associated pulmonary hypertension
Author: Gilbane, A.
ISNI:       0000 0004 8502 1854
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2015
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Up to 10 percent of systemic sclerosis (SSc) patients develop pulmonary arterial hypertension (PAH). This risk persists throughout the disease and is time dependent, suggesting that SSc operates as a susceptibility factor. Outcomes for SSc-PAH patients remain poor compared with heritable (HPAH) or idiopathic (HPAH) forms, despite clinical and pathological similarities. Whereas susceptibility in HPAH and HPAH is strongly associated with gene mutations that lead to reduced expression of functional bone morphogenetic protein type II receptor (BMPRII), these mutations have not been observed in SSc-PAH. My initial aim was to investigate BMPRII expression and downstream signalling pathways in whole lung tissue and explant cultured fibroblasts derived from a murine model of SSc (TβRIIΔk-fib) that is susceptible to developing PAH Complementary studies examined SSc or control lung tissue and fibroblasts. My results suggest reduced BMPRII levels, impaired signalling and altered receptor turnover could be due to increased TGFβ activity in a model of SSc-PAH. Similarly a significant reduction in BMPRII expression is observed in SSc lung tissue and fibroblasts. Increased proteasomal degradation of BMPRII appears to underlie this and may result from heightened TGFβ activity. Proteasomal inhibition restored BMPRII expression and cellular responses. Collectively suggesting that impaired TGFβ/BMP signalling leading to increased receptor degradation, may promote PAH susceptibility in SSc and provide a unifying mechanism across different forms of PAH. Since more than one cell type contribute to the development of PAH and the pathophysiology of the disease BMPRII expression and TGFβ responses in pulmonary arterial smooth muscle cells (PASMCs) were also investigated. Initial studies generated a synthetic "disease" like PASMC that also displayed a reduction in BMPRII expression and increased response to TGFβ, which was similar to IPAH cells Finally, the role of epigenetic inhibition in the TβRIIΔk-fib model was investigated. The epigenetic inhibitor JQ1 was able to attenuate the spontaneous development of PAH in the TβRIIΔk-fib model of PAH. Taken together, work described in this thesis strongly suggests that a reduction in BMPRII is a susceptibility factor to the development of PAH in a pre-clinical model of SSc and in SSc patients.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.789832  DOI: Not available
Share: